Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	308 Pages	Coherent Market Insights	May, 2022	CMI17213531

Best Price Guarantee
Price	from $4,500
Length	308 Pages
Publisher	Coherent Market Insights
Published Date	May, 2022
SKU	CMI17213531

Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study:

This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:

Global Autism Spectrum Disorder Therapeutics Market, By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
Global Autism Spectrum Disorder Therapeutics Market, By Age Group:
Child
Adult
Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Autism Spectrum Disorder Therapeutics Market, By Region:
North America
By Country:
U.S.
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Canada
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Germany
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Italy
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Spain
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
France
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Russia
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Europe
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
China
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Japan
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
India
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
ASEAN
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Australia
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
South Korea
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Asia Pacific
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Mexico
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Argentina
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Latin America
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Israel
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Middle East
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Central Africa
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North Africa
By Drug Type:
Aripiprazole
Risperidone
Melatonin
CM-AT
Bumetanide
Balovaptan
By Age Group:
Child
Adult
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
F. Hoffmann-La Roche AG.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Neurim Pharmaceuticals, Inc.
Yamo Pharmaceuticals LLC
Servier Laboratories Ltd.
Otsuka Holdings Co. Ltd.
Curemark LLC
Oryzon Genomics S.A.
GW Pharmaceuticals Plc.
Teva Pharmaceutical Industries Ltd.
Zynerba Pharmaceuticals Inc.
Stalicla SA.
Novartis AG
Pfizer, Inc.
Bristol Myers Squibb.
“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption: Research Objectives; Assumptions; Abbreviations
2. Market Overview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Drug Type; Market Snippet, By Age Group; Market Snippet, By Distribution Channel; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Market Trends; Key Developments; Regulatory Landscape; Collaborations & Partnerships; Epidemiology Analysis; Pipeline Analysis & Approved Product Analysis; Regulatory Scenario; Reimbursement Scenario; Porter’s Five Forces model
4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Aripiprazole; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Risperidone; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Melatonin; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); CM-AT; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Bumetanide; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Balovaptan; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Child; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Adult; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, 2022 and 2028 (%); Y-o-Y Growth Analysis, 2017 - 2028; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2017 - 2028, (US$ Million): Introduction; Market Share Analysis, By Region, 2022 and 2028 (%); Y-o-Y Growth Analysis, By Region, 2017 - 2028; Regional Trends; North America; Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million); Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); U.S.; Canada; Europe; Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million); Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million); Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); China; Japan; India; ASEAN; Australia; South Korea; Rest of Asia Pacific; Latin America; Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million); Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Africa; Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million); Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million); North Africa; Central Africa; South Africa; Middle East; Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million); Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million); Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million); Market Size and Forecast, By Country, 2017 - 2028, (US$ Million); GCC; Israel; Rest of Middle East
8. Competitive Landscape: Company Profiles; F. Hoffmann-La Roche AG; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Neurim Pharmaceuticals, Inc.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Yamo Pharmaceuticals LLC; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Servier Laboratories Ltd.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Otsuka Holdings Co. Ltd.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Curemark LLC; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Oryzon Genomics S.A.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; GW Pharmaceuticals Plc.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Teva Pharmaceutical Industries Ltd.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Zynerba Pharmaceuticals Inc.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; STALICLA SA; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Novartis AG; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Pfizer, Inc.; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Bristol Myers Squibb; Company Overview; Product Portfolio; Financial Performance; Recent Highlights; Strategies; Analyst Views
9. Section: References; Research Methodology; About Us and Sales Contact; *Browse 38 market data tables and 27 figures on "Autism Spectrum Disorder Therapeutics Market” - Global forecast to 2028”